Y Intercept Hong Kong Ltd purchased a new stake in shares of Enhabit, Inc. (NYSE:EHAB – Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 57,014 shares of the company’s stock, valued at approximately $450,000. Y Intercept Hong Kong Ltd owned about 0.11% of Enhabit at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in EHAB. FMR LLC grew its stake in shares of Enhabit by 138.4% during the third quarter. FMR LLC now owns 3,388 shares of the company’s stock worth $27,000 after buying an additional 1,967 shares during the last quarter. Quarry LP boosted its holdings in shares of Enhabit by 242.2% during the 2nd quarter. Quarry LP now owns 3,703 shares of the company’s stock valued at $33,000 after acquiring an additional 2,621 shares in the last quarter. Gladius Capital Management LP grew its position in Enhabit by 78.2% during the 3rd quarter. Gladius Capital Management LP now owns 6,259 shares of the company’s stock worth $49,000 after acquiring an additional 2,747 shares during the last quarter. Stoneridge Investment Partners LLC acquired a new position in Enhabit in the 3rd quarter worth about $81,000. Finally, Canada Pension Plan Investment Board bought a new position in Enhabit in the second quarter valued at about $93,000.
Insider Activity at Enhabit
In other Enhabit news, Director Stuart M. Mcguigan purchased 15,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were purchased at an average cost of $8.81 per share, with a total value of $132,150.00. Following the completion of the purchase, the director now owns 46,810 shares in the company, valued at $412,396.10. This represents a 47.15 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey Bolton purchased 4,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the acquisition, the director now directly owns 98,144 shares in the company, valued at approximately $852,871.36. This represents a 4.25 % increase in their position. The disclosure for this purchase can be found here. 1.90% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Analysis on EHAB
Enhabit Price Performance
Shares of EHAB opened at $8.52 on Monday. The business has a 50-day moving average of $7.56 and a 200-day moving average of $8.30. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.46 and a quick ratio of 1.46. The company has a market capitalization of $428.42 million, a price-to-earnings ratio of -3.67 and a beta of 1.89. Enhabit, Inc. has a 1 year low of $6.85 and a 1 year high of $11.74.
Enhabit (NYSE:EHAB – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.01). Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. The firm had revenue of $253.60 million for the quarter, compared to the consensus estimate of $261.69 million. During the same quarter in the previous year, the business posted $0.03 EPS. As a group, equities research analysts anticipate that Enhabit, Inc. will post 0.22 earnings per share for the current year.
Enhabit Company Profile
Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.
Recommended Stories
- Five stocks we like better than Enhabit
- Most Volatile Stocks, What Investors Need to Know
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- ESG Stocks, What Investors Should Know
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Using the MarketBeat Dividend Yield Calculator
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.